Arovella Therapeutics Ltd
E4NA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,815.30 | 5.00 | -0.06% |
CAC 40 | 7,829.29 | 72.96 | -0.92% |
DAX 40 | 24,255.31 | 201.50 | -0.82% |
Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
FTSE 100 | 8,941.12 | 34.54 | -0.38% |
HKSE | 24,239.47 | 99.90 | 0.41% |
NASDAQ | 20,585.53 | 45.14 | -0.22% |
Nikkei 225 | 39,459.62 | 110.06 | -0.28% |
NZX 50 Index | 12,678.69 | 7.99 | -0.06% |
S&P 500 | 6,259.75 | 20.71 | -0.33% |
S&P/ASX 200 | 8,570.40 | 9.70 | -0.11% |
SSE Composite Index | 3,528.67 | 18.49 | 0.53% |